• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Comput Struct Biotechnol J . Collaborative effects of 2019-nCoV-Spike mutants on viral infectivity

tetano

Editor, Senior Moderator
Comput Struct Biotechnol J


. 2023 Oct 17:21:5125-5135.
doi: 10.1016/j.csbj.2023.10.030. eCollection 2023. Collaborative effects of 2019-nCoV-Spike mutants on viral infectivity

Senbiao Fang[SUP] 1 [/SUP], Chuqi Lei[SUP] 1 [/SUP], Meng Li[SUP] 2 [/SUP], Yongfan Ming[SUP] 1 [/SUP], Liren Liu[SUP] 3 [/SUP], Xuming Zhou[SUP] 2 [/SUP], Min Li[SUP] 1 [/SUP]



Affiliations
Abstract

Background: The emerging mutants of the 2019-nCoV coronavirus are posing unprecedented challenges to the pandemic prevention. A thorough, understanding of the mutational characterization responsible for the pathogenic mechanisms of mutations in 2019-nCoV-Spike is indispensable for developing effective drugs and new vaccines.
Methods: We employed computational methods and viral infection assays to examine the interaction pattern and binding affinity between ACE2 and both single- and multi-mutants of the Spike proteins.
Results: Using data from the CNCB-NGDC databank and analysis of the 2019-nCoV-Spike/ACE2 interface crystal structure, we identified 31 amino acids that may significantly contribute to viral infectivity. Subsequently, we performed molecular dynamics simulations for 589 single-mutants that emerged from the nonsynonymous substitutions of the aforementioned 31 residues. Ultimately, we discovered 8 single-mutants that exhibited significantly higher binding affinities (<-65.00 kcal/mol) to ACE2 compared with the wild-type Spike protein (-55.07 kcal/mol). The random combination of these 8 single-mutants yielded 184 multi-mutants, of which 60 multi-mutants exhibit markedly enhanced binding affinities (<-65.00 kcal/mol). Moreover, the binding free energy analyses of all 773 mutants (including 589 single- and 184 multi-mutants) revealed that Y449R and S494R had a synergistic effect on the binding affinity with other mutants, which were confirmed by virus infection assays of six randomly selected multi-mutants. More importantly, the findings of virus infection assay further validated a strong association between the binding free energy of Spike/ACE2 complex and the viral infectivity.
Conclusions: These findings will greatly contribute to the future surveillance of viruses and rational design of therapeutics.

Keywords: COVID-19; Infection assay; Molecular dynamics simulations; Multi-mutant; Spike.

 
Back
Top Bottom